ZVRA

Zevra TherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$18.00

Analysis reference price unavailable

Analysis 2026-07-25 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$11.50

Analysis reference price unavailable

Analysis 2026-07-25 · RankAlpha Sentiment Codex

B-

Bear case

35%

Probability

Target price

$6.00

Analysis reference price unavailable

Analysis 2026-07-25 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-07-25

AI commentary

News tone is sharply negative after the July 24 EMA setback, with packet headlines indicating a substantial sell-off. The company source confirms the negative opinion and planned re-examination, while the exact post-release close-to-close reaction and analyst revisions are not fully available. Social coverage is absent, and the peer set is loose; this supports a cautious monitoring stance rather than a high-conviction directional call.

RankAlpha Sentiment Codex - 2026-07-25

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-07-24catalystNegative EMA opinion on arimoclomol EU applicationHigh impact

The CHMP adopted a negative opinion for arimoclomol in NPC; Zevra plans to request re-examination. This is the dominant near-term sentiment driver and materially delays European expansion. [#IR-2026-07-24] [#EMA-2026-07-24]

2026-10-23eventPotential EMA re-examination requestMedium impact

Zevra intends to submit a re-examination request and supporting explanation under European regulatory procedures. The request preserves optionality but does not establish a favorable outcome. [#IR-2026-07-24]

2026-12-31catalystU.S. MIPLYFFA commercial execution and cash runwayHigh impact

Q1 2026 revenue rose 78% year over year to $36.2 million, including $24.6 million of MIPLYFFA revenue; Zevra reported $236.8 million of cash after completing the SDX sale and repaying its term loan. [#SEC-8K-2026-05-06]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-25 • Updated nightlySource: Internal modelMethodology